Dean Emma, Khoja Leila, Clamp Andrew, Jayson Gordon C, Goonetilleke Dilly, Conway Alicia M, Hasan Jurjees
The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK.
Division of Molecular & Clinical Cancer Sciences, University of Manchester, Manchester, M13 9NT, UK.
Future Oncol. 2017 Mar;13(6):513-521. doi: 10.2217/fon-2016-0431. Epub 2017 Jan 18.
Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood.
This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO.
At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01).
The Manchester Bowel Obstruction Score may aide treatment stratification.
对卵巢癌所致恶性肠梗阻（MBO）的了解尚少。
这项回顾性队列研究分析了129例患有卵巢癌和MBO的患者。
就诊时，69例（53%）为铂类耐药，37例（29%）铂类敏感，23例（18%）未接受过化疗。在MBO发作后接受化疗的患者中，未接受过化疗的患者中位总生存期（OS）为107天，铂类敏感或铂类耐药患者的中位总生存期分别为83天和86天（p = 0.98）。与化疗（152天）或手术（124天）相比，最佳支持治疗的OS较差（45天；p < 0.001）。使用东部肿瘤协作组和梗阻程度的曼彻斯特肠梗阻评分可区分患者的中位OS，分别为181天（均无）、98天（一项）和42天（两项；p < 0.01）。
曼彻斯特肠梗阻评分可能有助于治疗分层。
